NAFDAC Registration & Regulatory Affairs (R &R) Directorate Guidelines On Variations To A Registered Vaccine for Humans
Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria
These guidelines apply to marketing authorization (MA) Holders intending to make changes to the quality section of the dossier as well as to the safety, efficacy and product labelling information for an antigen, intermediate or a finished vaccine product. This guidance should be read in conjunction with the NAFDAC guidelines on variations to a registered pharmaceutical product. It provides guidance for MA holders on the regulation of changes to the original MA dossier or product license for an approved vaccine in terms of procedures and criteria for the appropriate categorization and reporting of changes, and the data required to enable NAFDAC to evaluate the impact of the change on the quality, safety and efficacy of the vaccine.
Process Flow
Department of Registration and Regulatory Affairs ⬤
Office of the Director General NAFDAC ⬤
Office of the Permanent Secretary, Ministry of Health ⬤
Office of the Minister of State for Health ⬤
Office of the Minister of Health ⬤
Federal Executive Council ⬤
NAFDAC Registration & Regulatory Affairs (R &R) Directorate Guidelines On Variations To A Registered Vaccine for Humans Current Version
January 2022
These guidelines apply to marketing authorization (MA) Holders intending to make changes to the quality section of the dossier as well as to the safety, efficacy and product labelling information for an antigen, intermediate or a finished vaccine product. This guidance should be read in conjunction with the NAFDAC guidelines on variations to a registered pharmaceutical product. It provides guidance for MA holders on the regulation of changes to the original MA dossier or product license for an approved vaccine in terms of procedures and criteria for the appropriate categorization and reporting of changes, and the data required to enable NAFDAC to evaluate the impact of the change on the quality, safety and efficacy of the vaccine.
Thank you for requesting an expert analysis
A member of our team will review your request and reply back to the email address on file.